Systems Bio
Drug development is a highly rewarding yet inherently risky process, beginning with target selection. Choosing an incorrect drug target can result not only in significant financial losses but, more critically, in the loss of valuable time. This can cause irreparable harm to pharmaceutical companies and, most importantly, patients. This risk can be significantly mitigated through well-strategized data-driven approaches to target selection and validation.
Omics data provide highly accurate insights into the molecular landscape for drug target selection and validation. Specifically, Next-Generation Sequencing (NGS) and single-cell technologies enable experimental biologists to generate large datasets in a relatively short time, shifting the bottleneck to information processing. To fully leverage these extensive datasets, strong expertise in Bioinformatics and AI is indispensable.
The mission of Systems Biology Consulting & Analytics (Systems Bio) is to accelerate clinical and translational discoveries by harnessing the power of Bioinformatics and AI. To achieve this, Systems Bio supports biotechnology and pharmaceutical enterprises of all sizes in planning genomic experiments, as well as generating, analyzing and interpreting genomic data to discover and validate drug targets.
Reach out to us to learn about the ways how Systems Bio can help your life sciences organization to leverage genomics data for new discoveries.